852949-30-5

Basic information

• Product Name: [4-(3'-benzyl-4'-hydroxy-benzyl)-3,5-dimethylphenoxy]methylphosphonic acid
• Synonyms: [4-(3'-benzyl-4'-hydroxy-benzyl)-3,5-dimethylphenoxy]methylphosphonic acid
• CAS NO: 852949-30-5
• Molecular Weight: 412.422
• Mol File: 852949-30-5.mol

Chemical Properties

• CAS DataBase Reference: [4-(3'-benzyl-4'-hydroxy-benzyl)-3,5-dimethylphenoxy]methylphosphonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(3'-benzyl-4'-hydroxy-benzyl)-3,5-dimethylphenoxy]methylphosphonic acid(852949-30-5)
• EPA Substance Registry System: [4-(3'-benzyl-4'-hydroxy-benzyl)-3,5-dimethylphenoxy]methylphosphonic acid(852949-30-5)

Safety Data

• Hazardous Substances Data: 852949-30-5(Hazardous Substances Data)

Upstream product

• 1282618-57-8 C₁₆H₂₇O₅P 
• 28636-93-3 2,6-dimethyl-4-hydroxybenzyl alcohol 
• 108-68-9 3,5-Dimethylphenol 

Downstream Products

• 1282618-52-3 C₃₆H₄₇O₈P 
• 1282618-49-8 di(pivaloyloxymethyl) [4-(3'-benzyl-4'-hydroxybenzyl)-3,5-dimethylphenoxy]methylphosphonate 

Relevant articles and documents

THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF

A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or thyroid hormone axis.

Novel Phosphinic Acid-Containing Thyromimetics

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS

The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.